14 Outcomes With First-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) vs Physician’s Choice Combination Chemotherapy (combo CT) by Age in Pre/Perimenopausal Patients (pts) With Aggressive HR+/HER2– Advanced Breast Cancer (ABC): A Subgroup Analysis of the RIGHT Choice TrialByNagi El Saghir,Yoon Sim Yap,Yesim Eralp,Seock-Ah Im,Hamdy Abdel Azim,Julie Rihani,Nikita Volkov,Shin-Cheh Chen,Hakan Harputluoglu,Patrapim Sunpaweravong,Yuan-Ching Chang,Teresa Delgar Alfaro,Jiwen Wu,Huilin Hu,Melissa Gao,Yen-Shen LuAugust 15th 2024
16 Primary Results From the Randomized Phase II RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2− Advanced Breast Cancer Treated With Ribociclib + Endocrine Therapy vs Physician’s Choice Combination ChemotherapyByMelissa Gao,Yen-Shen Lu,Eznal Izwadi Bin Mohd Mahidin,Hamdy Abdel Azim,Yesim Eralp,Yoon Sim Yap,Seock-Ah Im,Julie Rihani,James Bowles,Teresa Delgar Alfaro,Jiwen Wu,Khemaies Slimane,Nagi El SaghirApril 28th 2023
50 Pooled Exploratory Analysis of Survival in Patients (pts) With HR+/ HER2− Advanced Breast Cancer (ABC) and Visceral Metastases (mets) Treated With Ribociclib (RIB) + Endocrine Therapy (ET) in the MONALEESA (ML) TrialsByDenise A. Yardley, MD,Yoon Sim Yap,Hamdy Abdel Azim,Richard De Boer,Mario Campone,Alistair Ring,Michelino De Laurentiis,Joyce A. O’Shaughnessy,Javier Cortes,Yogesh Chattar,Astrid Thuerigen,Juan Pablo Zarate,Liz SantarsieroApril 27th 2023